Clinical Characterization of Targetable Mutations (BRAF V600E and KRAS G12C) in Advanced Colorectal Cancer—A Nation-Wide Study

BRAF V600E and KRAS mutations that occur in colorectal cancer (CRC) define a subpopulation of patients with an inferior prognosis. Recently, the first BRAF V600E-targeting therapy has been approved and novel agents targeting KRAS G12C are being evaluated in CRC. A better understanding of the clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Potocki, Paweł M., Wójcik, Piotr, Chmura, Łukasz, Goc, Bartłomiej, Fedewicz, Marcin, Bielańska, Zofia, Swadźba, Jakub, Konopka, Kamil, Kwinta, Łukasz, Wysocki, Piotr J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219350/
https://www.ncbi.nlm.nih.gov/pubmed/37240418
http://dx.doi.org/10.3390/ijms24109073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219350/
https://www.ncbi.nlm.nih.gov/pubmed/37240418
http://dx.doi.org/10.3390/ijms24109073

Ejemplares similares